GB1518121A - Agent for intravascular administration - Google Patents

Agent for intravascular administration

Info

Publication number
GB1518121A
GB1518121A GB24288/75A GB2428875A GB1518121A GB 1518121 A GB1518121 A GB 1518121A GB 24288/75 A GB24288/75 A GB 24288/75A GB 2428875 A GB2428875 A GB 2428875A GB 1518121 A GB1518121 A GB 1518121A
Authority
GB
United Kingdom
Prior art keywords
agent
diagnostic
particles
polysaccharide
june
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
GB24288/75A
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pfizer Health AB
Original Assignee
Pharmacia AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacia AB filed Critical Pharmacia AB
Publication of GB1518121A publication Critical patent/GB1518121A/en
Expired legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B31/00—Preparation of derivatives of starch
    • C08B31/003—Crosslinking of starch
    • C08B31/006—Crosslinking of derivatives of starch

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Polymers & Plastics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Materials Engineering (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Pathology (AREA)
  • Rheumatology (AREA)
  • Toxicology (AREA)
  • Urology & Nephrology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
GB24288/75A 1974-06-06 1975-06-05 Agent for intravascular administration Expired GB1518121A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE7407462A SE420565B (sv) 1974-06-06 1974-06-06 Hjelpmedel for intravaskuler administraring for anvendning i samband med intravaskuler administrering av en losning eller en suspension av ett diagnostiseringsmedel

Publications (1)

Publication Number Publication Date
GB1518121A true GB1518121A (en) 1978-07-19

Family

ID=20321349

Family Applications (1)

Application Number Title Priority Date Filing Date
GB24288/75A Expired GB1518121A (en) 1974-06-06 1975-06-05 Agent for intravascular administration

Country Status (9)

Country Link
US (1) US4124705A (enExample)
JP (1) JPS6125689B2 (enExample)
AU (1) AU8164775A (enExample)
CA (1) CA1037950A (enExample)
DE (1) DE2524279A1 (enExample)
FR (1) FR2273555A1 (enExample)
GB (1) GB1518121A (enExample)
NL (1) NL7506757A (enExample)
SE (1) SE420565B (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1935421A1 (en) 2000-02-08 2008-06-25 Euro-Celtique S.A. Controlled-release compositions containing opioid agonist and antagonist

Families Citing this family (69)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5283960A (en) * 1976-01-01 1977-07-13 Pharmacia Ab Medicine for administrating in blood
DE2908437A1 (de) * 1979-03-05 1980-09-18 Fresenius Chem Pharm Ind Vernetzte hydroxyaethylstaerke
US4276885A (en) * 1979-05-04 1981-07-07 Rasor Associates, Inc Ultrasonic image enhancement
US4385046A (en) * 1980-12-15 1983-05-24 Minnesota Mining And Manufacturing Company Diagnostic radio-labeled polysaccharide derivatives
US4431626A (en) * 1981-05-27 1984-02-14 The Regents Of The University Of California Tc-99m Labeled carrier for imaging
FR2548902B1 (fr) * 1983-07-13 1986-04-11 Guerbet Sa Gel pour embolisation therapeutique
SE463651B (sv) * 1983-12-21 1991-01-07 Nycomed As Diagnostikum och kontrastmedel
US5266333A (en) * 1985-03-06 1993-11-30 American Cyanamid Company Water dispersible and water soluble carbohydrate polymer compositions for parenteral administration of growth hormone
US4680171A (en) * 1985-03-15 1987-07-14 William Shell Visualization of a bloodstream circulation with biodegradable microspheres
JPS62236839A (ja) * 1986-04-08 1987-10-16 Yoshiaki Motozato 架橋されたグルコマンナン球状粒子及びその製法
GB8801646D0 (en) * 1988-01-26 1988-02-24 Nycomed As Chemical compounds
US5948387A (en) * 1990-06-01 1999-09-07 Imarx Pharmaceutical Corp. Contrast media for ultrasonic imaging
US5420176A (en) * 1990-06-01 1995-05-30 Imarx Pharmaceutical Corp. Contrast media for ultrasonic imaging
US5202352A (en) * 1990-08-08 1993-04-13 Takeda Chemical Industries, Ltd. Intravascular embolizing agent containing angiogenesis-inhibiting substance
US5603956A (en) * 1990-11-27 1997-02-18 Labopharm Inc. Cross-linked enzymatically controlled drug release
US5233995A (en) * 1991-11-21 1993-08-10 Sterling Winthrop Inc. Encapsulated particles useful as contrast agents in ultrasound and x-ray imaging compositions and methods
EP0651634B1 (en) * 1992-07-24 1996-05-08 Labopharm Inc. Cross-linked polyhydroxylic material for enzymatically controlled drug release
US5514379A (en) * 1992-08-07 1996-05-07 The General Hospital Corporation Hydrogel compositions and methods of use
SE9303574D0 (sv) * 1993-11-01 1993-11-01 Kabi Pharmacia Ab Composition for drug delivery and method the manufacturing thereof
WO1996039464A1 (en) * 1995-06-06 1996-12-12 C.R. Bard, Inc. Process for the preparation of aqueous dispersions of particles of water-soluble polymers and the particles obtained
US6214331B1 (en) 1995-06-06 2001-04-10 C. R. Bard, Inc. Process for the preparation of aqueous dispersions of particles of water-soluble polymers and the particles obtained
US7435425B2 (en) 2001-07-17 2008-10-14 Baxter International, Inc. Dry hemostatic compositions and methods for their preparation
US8603511B2 (en) 1996-08-27 2013-12-10 Baxter International, Inc. Fragmented polymeric compositions and methods for their use
US8303981B2 (en) 1996-08-27 2012-11-06 Baxter International Inc. Fragmented polymeric compositions and methods for their use
US7871637B2 (en) 1996-08-27 2011-01-18 Baxter International Inc. Dry hemostatic compositions and methods for their preparation
US6066325A (en) 1996-08-27 2000-05-23 Fusion Medical Technologies, Inc. Fragmented polymeric compositions and methods for their use
US6261320B1 (en) 1996-11-21 2001-07-17 Radiance Medical Systems, Inc. Radioactive vascular liner
US6491619B1 (en) 1997-01-31 2002-12-10 Endologix, Inc Radiation delivery catheters and dosimetry methods
US5782742A (en) 1997-01-31 1998-07-21 Cardiovascular Dynamics, Inc. Radiation delivery balloon
US6458069B1 (en) 1998-02-19 2002-10-01 Endology, Inc. Multi layer radiation delivery balloon
US5993374A (en) * 1997-06-17 1999-11-30 Radiance Medical Systems, Inc. Microcapsules for site-specific delivery
US6048299A (en) * 1997-11-07 2000-04-11 Radiance Medical Systems, Inc. Radiation delivery catheter
US6149574A (en) * 1997-12-19 2000-11-21 Radiance Medical Systems, Inc. Dual catheter radiation delivery system
EP1056515A1 (en) 1998-02-19 2000-12-06 Radiance Medical Systems Inc. Radioactive stent
US6203778B1 (en) * 1998-12-08 2001-03-20 The Regents Of The University Of California Particulate radiopaque contrast agent for diagnostic imaging and microvascular characterization
US9080146B2 (en) 2001-01-11 2015-07-14 Celonova Biosciences, Inc. Substrates containing polyphosphazene as matrices and substrates containing polyphosphazene with a micro-structured surface
US8834864B2 (en) 2003-06-05 2014-09-16 Baxter International Inc. Methods for repairing and regenerating human dura mater
US7927626B2 (en) * 2003-08-07 2011-04-19 Ethicon, Inc. Process of making flowable hemostatic compositions and devices containing such compositions
US9114162B2 (en) 2004-10-25 2015-08-25 Celonova Biosciences, Inc. Loadable polymeric particles for enhanced imaging in clinical applications and methods of preparing and using the same
US20210299056A9 (en) 2004-10-25 2021-09-30 Varian Medical Systems, Inc. Color-Coded Polymeric Particles of Predetermined Size for Therapeutic and/or Diagnostic Applications and Related Methods
AU2005298344B2 (en) 2004-10-25 2011-02-10 Varian Medical Systems, Inc. Loadable polyphosphazene-comprising particles for therapeutic and/or diagnostic applications and methods of preparing and using the same
US9107850B2 (en) 2004-10-25 2015-08-18 Celonova Biosciences, Inc. Color-coded and sized loadable polymeric particles for therapeutic and/or diagnostic applications and methods of preparing and using the same
AU2007267338B2 (en) 2006-05-31 2013-04-04 Baxter Healthcare S.A. Method for directed cell in-growth and controlled tissue regeneration in spinal surgery
TWI436793B (zh) 2006-08-02 2014-05-11 Baxter Int 快速作用之乾密封膠及其使用和製造方法
US8623842B2 (en) 2006-09-27 2014-01-07 Hemostasis, Llc Hemostatic agent and method
CL2008003219A1 (es) 2007-10-30 2009-10-09 Baxter Int Uso de una biomatriz de colageno biofuncional, multicapas y no porosa, que dirige el crecimiento celular dentro de los intersticios de la biomatriz de colageno, para tratar un defecto de una membrana visceral o parietal; y biomatriz utilizada.
US8642831B2 (en) 2008-02-29 2014-02-04 Ferrosan Medical Devices A/S Device for promotion of hemostasis and/or wound healing
US9061087B2 (en) * 2008-03-04 2015-06-23 Hemostasis, Llc Method of making a hemostatic sponge wound dressing comprising subjecting the sponge to water vapor
US9039783B2 (en) 2009-05-18 2015-05-26 Baxter International, Inc. Method for the improvement of mesh implant biocompatibility
CA2765117C (en) 2009-06-16 2017-07-11 Joris Hoefinghoff Hemostatic sponge
WO2011021175A2 (en) 2009-08-18 2011-02-24 Ben Gurion University Of The Negev Research And Development Authority System and method for analyzing imaging data
JP2013514093A (ja) 2009-12-16 2013-04-25 バクスター・インターナショナル・インコーポレイテッド 止血スポンジ
SA111320355B1 (ar) 2010-04-07 2015-01-08 Baxter Heathcare S A إسفنجة لايقاف النزف
JP6289096B2 (ja) 2010-06-01 2018-03-07 バクスター・インターナショナル・インコーポレイテッドＢａｘｔｅｒ Ｉｎｔｅｒｎａｔｉｏｎａｌ Ｉｎｃｏｒｐ０Ｒａｔｅｄ 乾燥した安定な止血組成物を作製するためのプロセス
WO2011151386A1 (en) 2010-06-01 2011-12-08 Baxter International Inc. Process for making dry and stable hemostatic compositions
WO2011151384A1 (en) 2010-06-01 2011-12-08 Baxter International Inc. Process for making dry and stable hemostatic compositions
US9381269B2 (en) 2011-04-13 2016-07-05 Avent, Inc. Biosorbable wound treatment device, process for making, and method of using the same
EP2766058B1 (en) 2011-10-11 2022-11-23 Baxter International Inc. Hemostatic compositions
ES2938568T3 (es) 2011-10-11 2023-04-12 Baxter Int Composiciones hemostaticas
SG11201401878SA (en) 2011-10-27 2014-09-26 Baxter Int Hemostatic compositions
CA2865349C (en) 2012-03-06 2021-07-06 Ferrosan Medical Devices A/S Pressurized container containing haemostatic paste
EP2825216B1 (en) 2012-06-12 2015-08-19 Ferrosan Medical Devices A/S Dry haemostatic composition
AU2014283170B2 (en) 2013-06-21 2017-11-02 Ferrosan Medical Devices A/S Vacuum expanded dry composition and syringe for retaining same
RU2678592C1 (ru) 2013-12-11 2019-01-30 Ферросан Медикал Дивайсиз А/С Сухая композиция, содержащая компонент, улучшающий экструзию
BR112017007466B1 (pt) 2014-10-13 2021-03-02 Ferrosan Medical Devices A/S método para preparar uma composição seca, método para reconstituir a composição seca, pasta, composição seca, recipiente, kit homeostático, e, uso de uma composição seca
BR112017013565B1 (pt) 2014-12-24 2021-12-28 Ferrosan Medical Devices A/S Seringa para retenção e mistura de primeira e segunda substâncias
RU2717356C2 (ru) 2015-07-03 2020-03-23 Ферросан Медикал Дивайсиз А/С Шприц для удерживания вакуума в состоянии хранения
JP6523510B1 (ja) 2018-03-30 2019-06-05 Ｊｘ金属株式会社 スパッタリングターゲット
KR20210008479A (ko) 2018-05-09 2021-01-22 훼로산 메디칼 디바이스 에이/에스 지혈 조성물을 제조하는 방법

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2626257A (en) * 1952-05-21 1953-01-20 Johnson & Johnson Medical dusting powder
NL252506A (enExample) * 1959-06-12
SE372421B (enExample) * 1968-04-01 1974-12-23 Minnesota Mining & Mfg
JPS5439444B2 (enExample) * 1971-08-21 1979-11-28

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1935421A1 (en) 2000-02-08 2008-06-25 Euro-Celtique S.A. Controlled-release compositions containing opioid agonist and antagonist

Also Published As

Publication number Publication date
NL7506757A (nl) 1975-12-09
FR2273555A1 (fr) 1976-01-02
CA1037950A (en) 1978-09-05
AU8164775A (en) 1976-12-02
FR2273555B1 (enExample) 1978-10-06
US4124705A (en) 1978-11-07
SE420565B (sv) 1981-10-19
DE2524279A1 (de) 1975-12-18
SE7407462L (sv) 1975-12-08
JPS517115A (enExample) 1976-01-21
JPS6125689B2 (enExample) 1986-06-17
DE2524279C2 (enExample) 1990-07-12

Similar Documents

Publication Publication Date Title
GB1518121A (en) Agent for intravascular administration
Bazzano et al. Digitalis intoxication: treatment with a new steroid-binding resin
ZA965686B (en) Cascade polymer complexes process for their production and pharmaceutical agents containing said complexes
NZ218948A (en) Pharmaceutical preparations containing viscous gels for administration by syringe
KR880008800A (ko) 난용성 활성성분을 위한 치료계
EP0067130A3 (en) Capsules containing the active principle of an allergen, and process for their preparation
JP2002541218A5 (enExample)
FR2285857A1 (fr) Agent de controle medical destine a etre administre par voie intravasculaire
ATE143257T1 (de) Arzneiabgabesystem, verfahren zu dessen herstellung sowie dessen verwendung
Chahinian et al. Experimental and clinical activity of mitomycin C and cis-diamminedichloroplatinum in malignant mesothelioma
Wu et al. Differences in leucocyte-endothelium interactions between normal and adenocarcinoma bearing tissues in response to radiation
GB1279356A (en) Process for the cryogenic preservation of blood and erythrocytes and products produced thereby
Ali et al. Myeloperoxidase exerts anti-tumor activity in glioma after radiotherapy
Brockstein et al. Phase II studies of bryostatin-1 in patients with advanced sarcoma and advanced head and neck cancer
EP0280135A3 (en) Protein c-inhibitor (pci) as a pharmaceutical and diagnostic agent, process for the preparation of such a pharmaceutical or diagnostic agent and a composition containing pci
Mapp, RK & McCarthy The effect of zinc sulphate and of bicitropeptide on tetracycline absorption
EP0079221A3 (en) Immune complex removal and tumor specific antibody generation by immobilized protein a perfusion and postperfusion drug infusion
Fitzgerald et al. A case of increased platelet anti-heparin factor in a patient with Raynaud's phenomena and gangrene, treated by aspirin
GB1421308A (en) Physiological saline solution
Servodidio et al. Presenting signs and symptoms of choroidal melanoma: what do they mean?
Magrì et al. Primary pancreatic actinomycosis: A case report and literature review
Slater Perianal abscess:" Have I excluded leukaemia"?
Bodansky Mechanism of action of methylene blue in treatment of methemoglobinemia
JPS517113A (enExample)
Murphy Fatal tetanus with brain‐stem involvement and myocarditis in an ex‐serviceman

Legal Events

Date Code Title Description
PS Patent sealed [section 19, patents act 1949]
PE20 Patent expired after termination of 20 years

Effective date: 19950604